Trial of Modifications to Radical Prostatectomy
Number: NCT01407263 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Memorial Sloan Kettering Cancer Center Sponsor Trial Information Trial Location(s) and Contact(s): |
MRI-Mapped Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS Trial
Number: NCT01411345 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2|Phase 3 Sponsor(s): University of Miami Sponsor Trial Information Trial Location(s) and Contact(s): |
MR-Guided Cryoablation of Prostate Bed Recurrences
Number: NCT01727284 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s): |
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
Number: NCT01913106 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1|Phase 2 Sponsor(s): The Methodist Hospital Research Institute Sponsor Trial Information Trial Location(s) and Contact(s): |
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
Number: NCT02064673 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): yair lotan|University of Texas Southwestern Medical Center Sponsor Trial Information Trial Location(s) and Contact(s): |
A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts
Number: NCT02266745 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Promontory Therapeutics Inc. Sponsor Trial Information Trial Location(s) and Contact(s): |
68Ga-PSMA PET-CT Scan for Diagnosis and Management of Prostate Cancer
Number: NCT02282137 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Ebrahim Delpassand|Radiomedix, Inc.|Excel Diagnostics and Nuclear Oncology Center|Radio Isotope Therapy of America Sponsor Trial Information Trial Location(s) and Contact(s): |
Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis
Number: NCT03047135 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|AstraZeneca Sponsor Trial Information Trial Location(s) and Contact(s): |
Prostate SBRT for Locally Recurrent Prostate Cancer After Prior Radiotherapy
Number: NCT03253744 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Sponsor Trial Information Trial Location(s) and Contact(s): |
Focal Salvage HDR Brachytherapy for Locally Recurrent Prostate Cancer in Patients Treated With Prior Radiotherapy
Number: NCT03312972 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1|Phase 2 Sponsor(s): Loyola University Sponsor Trial Information Trial Location(s) and Contact(s): |
Combination Immunotherapy in Biochemically Recurrent Prostate Cancer
Number: NCT03315871 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Sponsor Trial Information Trial Location(s) and Contact(s): |
Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate Cancer
Number: NCT03456843 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Yale University|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s): |
PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Number: NCT03460977 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Pfizer Sponsor Trial Information Trial Location(s) and Contact(s): |
Apalutamide With or Without Stereotactic Body Radiation Therapy in Treating Participants With Castration-Resistant Prostate Cancer (PILLAR)
Number: NCT03503344 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of California, San Francisco|Janssen Pharmaceuticals Sponsor Trial Information Trial Location(s) and Contact(s): |
Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy
Number: NCT03543189 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1|Phase 2 Sponsor(s): H. Lee Moffitt Cancer Center and Research Institute|Bristol-Myers Squibb Sponsor Trial Information Trial Location(s) and Contact(s): |
BEACON: HDR Brachytherapy, EBRT and STAD for the Treatment of Local and Pelvic Recurrence of Prostate Cancer After Radiation Therapy
Number: NCT03553602 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1|Phase 2 Sponsor(s): Loyola University Sponsor Trial Information Trial Location(s) and Contact(s): |
Fluciclovine F18 or Ga68-PSMA PET/CT to Enhance Prostate Cancer Outcomes
Number: NCT03762759 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Emory University|Telix International Pty Ltd|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s): |
Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer
Number: NCT03796767 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Utah Sponsor Trial Information Trial Location(s) and Contact(s): |
A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery
Number: NCT03809000 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): RTOG Foundation, Inc.|Pfizer|Astellas Pharma Inc Sponsor Trial Information Trial Location(s) and Contact(s): |
WALNUTS for POWER: Polyphenols, Omega-3 Fatty Acids, Weight Loss, and EneRgy
Number: NCT03824652 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Stephen Freedland|California Walnut Commission|Cedars-Sinai Medical Center Sponsor Trial Information Trial Location(s) and Contact(s): |
Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer
Number: NCT03902951 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Jonsson Comprehensive Cancer Center|Janssen Inc. Sponsor Trial Information Trial Location(s) and Contact(s): |
Nivolumab in Biochemically Recurrent dMMR Prostate Cancer
Number: NCT04019964 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Bristol-Myers Squibb Sponsor Trial Information Trial Location(s) and Contact(s): |
Fluciclovine (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study
Number: NCT04175431 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Washington|Blue Earth Diagnostics Sponsor Trial Information Trial Location(s) and Contact(s): |
Radium-223 in Biochemically Recurrent Prostate Cancer
Number: NCT04206319 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Sponsor Trial Information Trial Location(s) and Contact(s): |
Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load
Number: NCT04336943 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Washington|AstraZeneca Sponsor Trial Information Trial Location(s) and Contact(s): |
Biomarker Monitoring of Prostate Cancer Patients With RSI MRI (ProsRSI)
Number: NCT04349501 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of California, San Diego Sponsor Trial Information Trial Location(s) and Contact(s): |
Randomized Phase II Trial of Salvage Radiotherapy for Prostate Cancer In 4 Weeks v. 2 Weeks
Number: NCT04422132 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Weill Medical College of Cornell University|Viewray Inc. Sponsor Trial Information Trial Location(s) and Contact(s): |
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Using PET/CT Imaging
Number: NCT04423211 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group Sponsor Trial Information Trial Location(s) and Contact(s): |
68Ga PSMA-11 PET/CT in Recurrent Prostate Cancer
Number: NCT04483414 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Dana Mathews|University of Texas Southwestern Medical Center Sponsor Trial Information Trial Location(s) and Contact(s): |
Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study
Number: NCT04484818 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group Sponsor Trial Information Trial Location(s) and Contact(s): |
White Button Mushroom Sup for the Reduction of PSA in Pts With Biochemically Rec or Therapy Naive Fav Risk Prostate CA
Number: NCT04519879 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): City of Hope Medical Center|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s): |
Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate Cancer
Number: NCT04600336 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s): |
Pacritinib for Biochemical Relapse After Definitive Treatment for Prostate Cancer
Number: NCT04635059 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Medical College of Wisconsin Sponsor Trial Information Trial Location(s) and Contact(s): |
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
Number: NCT04644068 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1|Phase 2 Sponsor(s): AstraZeneca Sponsor Trial Information Trial Location(s) and Contact(s): |
PyL in Patients With High Risk and Biochemically Recurrent Prostate Cancer
Number: NCT04700332 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Hoag Memorial Hospital Presbyterian Sponsor Trial Information Trial Location(s) and Contact(s): |
A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer
Number: NCT04709276 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Andrew J. Armstrong, MD|Bristol-Myers Squibb|Duke University Sponsor Trial Information Trial Location(s) and Contact(s): |
Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
Number: NCT04734730 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): City of Hope Medical Center|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s): |
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
Number: NCT04742361 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): ABX advanced biochemical compounds GmbH Sponsor Trial Information Trial Location(s) and Contact(s): |
Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer
Number: NCT04743934 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Andrew McDonald|University of Alabama at Birmingham Sponsor Trial Information Trial Location(s) and Contact(s): |
An Investigational Scan (68Ga-PSMA-11 PET/CT) for the Imaging of Prostate Cancer
Number: NCT04777071 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Washington Sponsor Trial Information Trial Location(s) and Contact(s): |
Phase II Study of Pencil Beam Scanning Proton Stereotactic Body Radiation Therapy for Prostate Cancer
Number: NCT04842890 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): The New York Proton Center Sponsor Trial Information Trial Location(s) and Contact(s): |
99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer
Number: NCT04857502 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Early Phase 1 Sponsor(s): Jonsson Comprehensive Cancer Center Sponsor Trial Information Trial Location(s) and Contact(s): |
Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization
Number: NCT04879940 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): H. Lee Moffitt Cancer Center and Research Institute Sponsor Trial Information Trial Location(s) and Contact(s): |
A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer
Number: NCT04898634 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Janssen Research & Development, LLC Sponsor Trial Information Trial Location(s) and Contact(s): |
Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy
Number: NCT04915508 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Jonsson Comprehensive Cancer Center Sponsor Trial Information Trial Location(s) and Contact(s): |
An Investigational Scan (rh PSMA 7.3 PET/MRI) for the Detection of Recurrent Disease and Aid in Radiotherapy Planning in Biochemically Recurrent Prostate Cancer
Number: NCT04978675 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): M.D. Anderson Cancer Center Sponsor Trial Information Trial Location(s) and Contact(s): |
Study of ADXS-504 Immunotherapy for Recurrent Prostate Cancer
Number: NCT05077098 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1 Sponsor(s): Mark Stein|Columbia University Sponsor Trial Information Trial Location(s) and Contact(s): |
Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors
Number: NCT05313191 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Not Applicable Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s): |
64Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer (SABRE)
Number: NCT05407311 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Sponsor Trial Information Trial Location(s) and Contact(s): |